Elanco reports 8% organic constant currency growth in Q2 2026, exceeding guidance and prompting an upward revision for annual targets.
Elanco Animal Health (ELAN) posted 8% organic constant currency revenue growth in Q2 2026, surpassing the high end of its guidance range. The company also outperformed on adjusted EBITDA and adjusted EPS, leading to a full-year guidance increase.
Prior guidance had projected 6%-7% organic constant currency growth for the year. The company now expects net leverage to reach approximately $3x by year-end 2026, aligning with earlier projections.
Management attributed the outperformance to strong execution and market demand, though no immediate market reaction was detailed in the earnings call insights.